Drawing on its broad portfolio of Mog (35-55) and other multiple sclerosis (MS) experimental autoimmune encephalomyelitis (EAE)-related peptides, AnaSpec has released SensoLyte anti-Mog Elisa kits
Myelin oligodendrocyte glycoprotein (Mog), a member of the immunoglobulin superfamily, is expressed exclusively in central nervous system myelin.
Recent studies suggest that Mog may function in the completion, compaction, and maintenance of myelin in the central nervous system.
Even though Mog physiological function is not entirely understood, studies have correlated the immune response of Mog to autoimmune mediated demyelination in several species.
Mog is able to induce encephalitogenic T cell response, autoantibody response, and produce relapsing-remitting neurological disease with an extensive plaque-like demyelination.
Autoantibody response to Mog (35-55) has been observed in multiple sclerosis (MS) patients and Mog (35-55)-induced experimental autoimmune encephalomyelitis (EAE) mice; however, the exact pathological role of anti-Mog (35-55) autoantibody is not known and is currently under vigorous investigation in the field.
AnaSpec's SensoLyte family of anti-Mog (35-55) IgG quantitative Elisa kits (mouse/rat) are designed to further the research of MS.
These kits are optimised to detect anti-Mog (35-55) mouse/rat IgG and IgG subtypes.
Using strips pre-coated with Mog (35-55) peptide and pre-blocked with BSA, the amount of anti-Mog IgG subtypes in serum or cerebrospinal fluid can be determined by Elisa and the absorbance read at 450nm.
